Latest Period
Q1 2026
Security Snapshot
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) Institutional Ownership
CUSIP: 03879J100
13F Institutional Holders and Ownership History from Q2 2015 to Q1 2026
Institutions Reporting
166
Shares (Excl. Options)
138,984,840
Price
$4.50
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Shares, without par value
- Symbol
- ABUS on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 138,984,840
- Total 13F value
- $625,429,886
- Portfolio coverage rank
- 0%
- Share change
- +16,930,355
- Value change
- +$75,356,451
- Number of holders
- 166
- Shares outstanding
- 197,420,670
- SEC-reported price per share
- $4.60
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ABUS - Arbutus Biopharma Corp - Common Shares, without par value is tracked under CUSIP 03879J100.
- 166 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 173 to 166 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $586,934,773 to $625,429,886.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 166 institutions filings for Q1 2026.
Security key
03879J100
Latest holder period
Q1 2026
13F holders
166
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
ABUS full holder history
Arbutus Biopharma Corp SEC filings
Arbutus Biopharma Corp company facts
Arbutus Biopharma Corp insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03879J100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
ABUS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | 20% | 0% | $127,808,150 | 38,847,462 | 0% | Roivant Sciences Ltd. | 21 Feb 2025 | |
| MORGAN STANLEY | 14% | +19% | $122,814,997 | +$20,788,104 | 25,910,337 | +20% | Morgan Stanley | 31 Dec 2025 |
| Two Seas Capital LP | 9.4% | +41% | $79,797,435 | +$25,664,056 | 18,557,543 | +47% | Two Seas Capital LP | 31 Mar 2026 |
| Whitefort Capital Management, LP | 8% | -1.2% | $71,074,174 | 15,794,261 | 0% | Whitefort Capital Master Fund, LP | 24 Apr 2026 |
As of 31 Mar 2026, 166 institutional investors reported holding 138,984,840 shares of Arbutus Biopharma Corp - Common Shares, without par value (ABUS). This represents 70% of the company’s total 197,420,670 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
64%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | 13% | 25,891,480 | -3% | 0.01% | $116,511,663 |
| Two Seas Capital LP | 9.4% | 18,557,543 | +47% | 3.9% | $83,508,944 |
| Whitefort Capital Management, LP | 7.6% | 14,930,885 | +12% | 20% | $67,188,983 |
| BlackRock, Inc. | 6.6% | 12,966,946 | -0.66% | 0% | $58,351,259 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.4% | 6,688,911 | 0% | 0% | $30,100,100 |
| Rubric Capital Management LP | 3.4% | 6,626,389 | +321% | 0.37% | $29,818,751 |
| STATE STREET CORP | 3.2% | 6,342,510 | +7.4% | 0% | $28,541,295 |
| BARCLAYS PLC | 2.2% | 4,316,095 | +1110% | 0.01% | $19,422,429 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 3,771,806 | +2.6% | 0% | $16,976,722 |
| ADAR1 Capital Management, LLC | 1.6% | 3,133,175 | -42% | 0.85% | $14,099,288 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.3% | 2,664,941 | -39% | 0.02% | $11,992,235 |
| BlackBarn Capital Partners LP | 1.3% | 2,500,000 | +35% | 3.4% | $11,250,000 |
| Legal & General Group Plc | 1.2% | 2,401,389 | +1856% | 0% | $10,806,252 |
| Woodline Partners LP | 1% | 2,010,172 | -8.1% | 0.03% | $9,045,774 |
| Jefferies Financial Group Inc. | 0.96% | 1,894,067 | 0.1% | $8,523,302 | |
| BANK OF AMERICA CORP /DE/ | 0.85% | 1,683,628 | -8.1% | 0% | $7,576,327 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.71% | 1,401,157 | -10% | 0% | $6,305,207 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.71% | 1,392,024 | 0% | 0% | $6,264,108 |
| OSAIC HOLDINGS, INC. | 0.68% | 1,348,127 | -0.01% | 0.01% | $6,066,571 |
| NORTHERN TRUST CORP | 0.65% | 1,277,859 | +3.3% | 0% | $5,750,368 |
| GOLDMAN SACHS GROUP INC | 0.56% | 1,100,434 | +49% | 0% | $4,951,954 |
| VANGUARD FIDUCIARY TRUST CO | 0.54% | 1,063,054 | 0% | 0% | $4,783,743 |
| CITIGROUP INC | 0.46% | 898,421 | +47% | 0% | $4,042,895 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 0.42% | 838,210 | -5.9% | 0% | $3,771,945 |
| Deltroit Asset Management (UK) LLP | 0.41% | 800,000 | 0.62% | $3,600,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
44
Latest
Q1 2026
Rows shown
1-25 of 44
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 138,984,840 | $625,429,886 | +$75,356,451 | $4.50 | 166 |
| 2025 Q4 | 122,028,178 | $586,934,773 | +$19,507,202 | $4.81 | 173 |
| 2025 Q3 | 118,168,575 | $536,370,600 | +$2,487,933 | $4.54 | 166 |
| 2025 Q2 | 118,112,086 | $364,964,865 | +$19,645,984 | $3.09 | 162 |
| 2025 Q1 | 111,778,063 | $390,115,968 | +$29,488,807 | $3.49 | 167 |
| 2024 Q4 | 104,075,822 | $340,339,884 | +$3,767,856 | $3.27 | 153 |
| 2024 Q3 | 101,100,254 | $389,229,670 | +$15,557,626 | $3.85 | 143 |
| 2024 Q2 | 96,687,257 | $298,333,597 | +$40,873,896 | $3.09 | 129 |
| 2024 Q1 | 83,370,717 | $215,132,214 | +$11,550,835 | $2.58 | 118 |
| 2023 Q4 | 78,913,089 | $197,297,266 | +$10,900,831 | $2.50 | 110 |
| 2023 Q3 | 70,841,695 | $143,815,507 | +$8,057,833 | $2.03 | 96 |
| 2023 Q2 | 66,235,432 | $152,407,843 | +$7,387,882 | $2.30 | 109 |
| 2023 Q1 | 62,470,799 | $189,264,221 | +$26,478,755 | $3.03 | 120 |
| 2022 Q4 | 54,227,682 | $126,382,359 | +$17,821,528 | $2.33 | 110 |
| 2022 Q3 | 46,620,587 | $89,144,270 | -$921,936 | $1.91 | 121 |
| 2022 Q2 | 35,268 | $93,574 | -$3,027,847 | $2.18 | 11 |
| 2022 Q1 | 43,886,769 | $130,608,351 | +$4,239,945 | $2.98 | 111 |
| 2021 Q4 | 39,679,851 | $154,349,574 | +$14,066,593 | $3.89 | 114 |
| 2021 Q3 | 34,872,896 | $149,655,492 | +$26,301,612 | $4.29 | 96 |
| 2021 Q2 | 28,908,795 | $87,633,862 | +$7,803,555 | $3.03 | 83 |
| 2021 Q1 | 25,991,001 | $86,467,063 | +$11,894,875 | $3.33 | 88 |
| 2020 Q4 | 21,915,953 | $77,813,914 | -$4,704,362 | $3.55 | 72 |
| 2020 Q3 | 24,142,348 | $75,528,504 | +$7,771,699 | $3.13 | 60 |
| 2020 Q2 | 26,122,191 | $47,560,467 | +$748,885 | $1.82 | 46 |
| 2020 Q1 | 26,281,827 | $26,537,879 | -$13,148,563 | $1.01 | 44 |